Portuguese Plant Opens Up Prospects For Hikma To Expand In Europe
Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.
You may also be interested in...
Hikma has expanded its European presence by establishing a subsidiary in France, marking its “official entry” into the major market following previous supplies through a third-party partner.
India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.